Generex Biotechnology Corporation announced earnings results for the third quarter ended April 30, 2021. For the third quarter, the company announced sales was USD 20,695 compared to USD 498,676 a year ago. Operating loss was USD 6.363 million compared to USD 3.574 million a year ago. Net income was USD 9.222 million compared to net loss of USD 5.626 million a year ago. Basic earnings per share from continuing operations was USD 0.08 compared to basic loss per share from continuing operations of USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.07 a year ago. For the nine months, sales was USD 109,130 compared to USD 2.077 million a year ago. Operating loss was USD 29.053 million compared to USD 12.681 million a year ago. Net loss was USD 25.588 million compared to USD 21.661 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.31 a year ago.